Evidence map›Paper›PMID 37752558›Full record

ArticleOrphanet journal of rare diseases2023

The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data.

Gema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M Boot, Maria Luisa Brandi, Karine Briot, Carmen de Lucas Collantes, Francesco Emma, Sandro Giannini, Dieter Haffner, Richard Keen and 10 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03193476 (An International, Multicentre, Prospective, Non-interventional Observational Registry for Patients With X-Linked Hypophosphatemia), which is not on this map. Cited by 41 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03193476 recruitingnot on this map

An International, Multicentre, Prospective, Non-interventional Observational Registry for Patients With X-Linked Hypophosphatemia (XLH)

Typeobservational_patient_registrySponsorKyowa Kirin Pharmaceutical Development LtdRan2017 to 2029Enrolled1,489ConditionsX-Linked Hypophosphatemia
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Real-world impact of treatment on growth in children with X-linked hypophosphatemia.The Journal of clinical endocrinology and metabolism · 2026
    Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Dental disease burden and management in children and young people with X-linked hypophosphataemia: a scoping review and service evaluation.European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry · 2026
    Article
  13. Impact of data sources and ascertainment methods on reporting paediatric genetic condition prevalence: A scoping review.Health information management : journal of the Health Information Management Association of Australia · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Switching from active vitamin D and phosphate supplementation to burosumab significantly corrects lower limb malalignment in pediatric X-linked hypophosphatemia.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025
    Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 17 institutions in 11 countries.

Gema AricetaDepartment of Pediatric Nephrology, Hospital Vall d'Hebron, Universitat Autonoma Barcelona, Barcelona, Spain. gema.ariceta@vallhebron.cat.ORCID 0000-0003-1763-1098
Signe Sparre Beck-NielsenCentre for Rare Diseases, Aarhus University Hospital, Åarhus, Denmark.
Annemieke M BootDepartment of Pediatrics, Division of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Maria Luisa BrandiFIRMO Foundation, Florence, Italy.
Karine BriotHôpital Cochin, Service de Rhumatologie, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate Filière OSCAR, AP-HP, Paris, France.
Carmen de Lucas CollantesUniversidad Autónoma de Madrid, Madrid, Spain.
Francesco EmmaDivision of Nephrology, Bambino Gesù Children's Hospital - IRCCS, Rome, Italy.
Sandro GianniniDepartment of Medicine, Clinica Medica 1, University of Padova, Padua, Italy.
Dieter HaffnerDepartment of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany.
Richard KeenRoyal National Orthopaedic Hospital, Stanmore, UK.
Elena LevtchenkoDepartment of Pediatric Nephrology and Development and Regeneration, University Hospitals Leuven, University of Leuven, Leuven, Belgium.
Outi MäkitieChildren's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
M Zulf MughalDepartment of Paediatric Endocrinology, Royal Manchester Children's Hospital, Manchester University Hospital's NHS Trust, Manchester, UK.
Ola NilssonDivision of Pediatric Endocrinology and Center for Molecular Medicine, Department of Women's and Children's Health, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Dirk SchnabelCenter for Chronically Sick Children, Pediatric Endocrinology, Charité, University Medicine Berlin, Berlin, Germany.
Liana Tripto-ShkolnikDivision of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Jonathan LiuKyowa Kirin International, Marlow, UK.
Angela WilliamsKyowa Kirin International, Marlow, UK.
Sue WoodKyowa Kirin International, Marlow, UK.
M Carola ZillikensBone Center, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Kyowa Kirin International (United Kingdom) · GBAarhus University · DKBambino Gesù Children's Hospital · ITCharité - Universitätsmedizin Berlin · DEErasmus MC · NLHôpital Cochin · FRHospital Infantil Universitario Niño Jesús · ESKU Leuven · BEMedizinische Hochschule Hannover · DEÖrebro University · SERoyal Manchester Children's Hospital · GBRoyal National Orthopaedic Hospital · GBTel Aviv University · ILUniversitat Autònoma de Barcelona · ESUniversity Medical Center Groningen · NLUniversity of Helsinki · FIUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundX-linked hypophosphatemia (XLH) is a rare, hereditary, progressive, renal phosphate-wasting disorder characterized by a pathological increase in FGF23 concentration and activity. Due to its rarity, diagnosis may be delayed, which can adversely affect outcomes. As a chronic disease resulting in progressive accumulation of musculoskeletal manifestations, it is important to understand the natural history of XLH over the patient's lifetime and the impact of drug treatments and other interventions. This multicentre, international patient registry (International XLH Registry) was established to address the paucity of these data. Here we present the findings of the first interim analysis of the registry.

resultsThe International XLH Registry was initiated in August 2017 and includes participants of all ages diagnosed with XLH, regardless of their treatment and management. At the database lock for this first interim analysis (29 March 2021), 579 participants had entered the registry before 30 November 2020 and are included in the analysis (360 children [62.2%], 217 adults [37.5%] and 2 whose ages were not recorded [0.3%]; 64.2% were female). Family history data were available for 319/345 (92.5%) children and 145/187 (77.5%) adults; 62.1% had biological parents affected by XLH. Genetic testing data were available for 341 (94.7%) children and 203 (93.5%) adults; 370/546 (67.8%) had genetic test results; 331/370 (89.5%) had a confirmed PHEX mutation. A notably longer time to diagnosis was observed in adults ≥ 50 years of age (mean [median] duration 9.4 [2.0] years) versus all adults (3.7 [0.1] years) and children (1.0 [0.2] years). Participants presented with normal weight, shorter length or height and elevated body mass index (approximately - 2 and + 2 Z-scores, respectively) versus the general population. Clinical histories were collected for 349 participants (239 children and 110 adults). General data trends for prevalence of bone, dental, renal and joint conditions in all participants were aligned with expectations for a typical population of people with XLH.

conclusionThe data collected within the International XLH Registry, the largest XLH registry to date, provide substantial information to address the paucity of natural history data, starting with demographic, family history, genetic testing, diagnosis, auxology and baseline data on clinical presentation.

Indexed as

Familial Hypophosphatemic RicketsGenetic Diseases, X-LinkedAdultChildChild, PreschoolDemographyFemaleHumansMaleMutationRegistriesFibroblast growth factor 23 (FGF23)Hypophosphatemic ricketsInternationalNatural historyOsteomalaciaPatient registryPHEX mutationRare diseaseX-linked hypophosphatemia (XLH)

Identifiers

PMID37752558
PMCPMC10523658
OpenAlexW4387077424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.